Trial Profile
Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary) ; Fluorouracil (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms GEP13-NEOTOP; NeoTOP
- Sponsors UNICANCER
- 06 Dec 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 16 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.